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Lymphatic mapping with sentinel lymphadenectomy
(SLND) has become the standard approach to intermediate
thickness melanoma at most melanoma centers worldwide.
The procedure has yielded numerous, unquestioned beneﬁts
for patients with melanoma, including providing vital
prognostic information and improving disease-free survival
with reduction of morbid regional nodal recurrences.
However, some uncertainty regarding the impact of the
procedure on overall survival persists.
1,2
Leiter and colleagues provide additional data to examine
SLND in this issue of the Annals of Surgical Oncology.
They present a retrospective series of the 879 patients with
intermediate thickness melanoma treated at the University
of Tuebingen from 1991 to 2005, half of whom had
undergone SLND (439) and half of whom did not (440).
These investigators were not participants in the Multicenter
Selective Lymphadenectomy Trial (MSLT1), and so their
data are independent of those of the randomized, prospec-
tive trial.
3 One of their stated goals was to contribute to the
evaluation of the procedure’s impact on survival. Their
analysis demonstrates remarkable consistency with the
ﬁndings of MSLT1 (Table 1).
Once again, the dominant prognostic importance of
sentinel node status is conﬁrmed, as is the impact on
disease-free survival, and they conﬁrm an identical risk of
in-transit recurrences with or without SLND.
3–6 As with
MSLT1 thus far, deﬁnitive evidence of an overall survival
beneﬁt among all patients was not found. At the third
interim analysis of MSLT1, there was an absolute 3%
improvement in 3-year melanoma-speciﬁc survival, which
was not statistically superior and vanished into wide con-
ﬁdence intervals by 5 years. In the current study, the
nonsigniﬁcant difference was 4%, although multivariate
analysis demonstrated a stronger trend toward beneﬁt in the
SLND group (p = 0.09). Earlier elective lymph node dis-
section results are nearly identical (4% at 5 years).
7
Why was there no difference in the overall group
comparisons? The most important reason is the absence of
nodal disease in the majority of patients. As with any tar-
geted therapy, if over 80% of patients do not demonstrate
the responding phenotype, it is extremely difﬁcult to
demonstrate an overall survival improvement. For exam-
ple, a trial of the monoclonal antibody trastuzumab would
not be likely to show an overall survival beneﬁt if subjects’
expression of the target antigen is unknown at the time of
randomization. The predictive biomarker here for response
to nodal surgery is within the node itself. Unfortunately, as
yet there is no way to accurately know the status of the
sentinel node until it is on the pathologist’s microscope.
This brings us to the ﬁnal group of striking similarities
of Leiter et al. and MSLT1: comparisons of the node-
positive patients. These comparisons have been approached
with marked statistical trepidation because patients were
not directly randomized into the node-positive groups,
which results in the possibility of bias by chance or through
an unidentiﬁed confounder. The statistically ideal trial, one
which randomizes patients with clinically occult nodal
metastases to immediate removal or to removal after the
disease has become clinically apparent, would clearly be
unethical. The debate in melanoma lymph node manage-
ment has never been about whether to removed diseased
lymph nodes, only when to do it.
How comparable are the two groups with lymph node
involvement in this study and MLST1? Again the similari-
ties are striking. The fraction of patients with nodal disease
in each treatment group, demonstrated by either positive
sentinelnode orbyclinical nodal recurrence, are identical in
the Leiter study and within 1% of each other in MSLT1,
when projected to 8 years of follow-up. There does not
appeartobeanexcessofpositivenodesintheSLNDgroups,
 Society of Surgical Oncology 2009
Published Online: 30 October 2009
M. Faries, MD
e-mail: fariesm@jwci.org
Ann Surg Oncol (2010) 17:18–20
DOI 10.1245/s10434-009-0782-0which suggests that virtually all positive sentinel nodes are
clinically signiﬁcant. Recent data from The Netherlands
suggest that isolated melanoma cells (\0.1 mm) in sentinel
nodes do not impart a worse prognosis than completely
negative nodes.
8 However, patients with such minimal dis-
easearealsothemostlikelytohavetheirdiseaseprogression
arrested by the SLND itself. Absence of recurrence among
thesepatientsmaybeevidenceoftherapeuticefﬁcacy,rather
than clinical insigniﬁcance.
In addition, comparisons of known prognostic variables
within the node-positive groups of both the Tuebingen
cohorts and MSLT1 show no indication of biologically
favorable characteristics in the SLND groups. In fact, what
differences there are tend to favor the nodal observation
groups. These include gender, ulceration, and level of inva-
sion in the Tuebingen series, and age in MLST1. Overall, it
seemsasurvivalbiasinfavoroftheSLNDgroupsisunlikely.
When survival comparisons of node-positive patients
are made in the two studies, the results are remarkably
similar and are not subtle. In each study, the risk of mel-
anoma death is cut approximately in half by the early
removal of nodal disease. This magnitude of difference
would be difﬁcult to explain through an unidentiﬁed,
uncontrolled bias in the two cohorts and clearly has major
clinical implications for those patients who harbor mi-
crometastases at the time of presentation. If we accept that
SLND improves survival in node-positive patients, and
with no operative mortality reported in major trials, overall
survival must be improved, though it might require a trial
of several thousand patients to prove it.
9
What then should we tell our patients with newly diag-
nosed, intermediate thickness melanoma about SLND? First,
for those without life-limiting comorbidities, it is an essential
part of their evaluation and treatment. Second, since a false-
negative SLND is at least as bad as no SLND at all, the pro-
cedureshouldbedoneatinstitutionswithadequateexperience
and expertise. Finally, if the patient harbors a lymph node
metastasis, removing it while it is clinically undetectable will
markedly reduce the risk of dying from melanoma.
Whether this last assertion has been proven beyond a
reasonable doubt depends on one’s deﬁnition of reason-
able. Perhaps additional follow-up in MSLT 1 will yield a
statistically signiﬁcant answer in the fourth interim or ﬁnal
analyses yet to come, but since the procedure is essential to
accurate staging, decreases disease recurrence, and can be
done with minimal morbidity, that particular question is
essentially moot. The important remaining question is
whether, in the setting of a positive sentinel node, there is a
beneﬁt to completion nodal dissection.
While current data demonstrate the beneﬁt of early
removal of micrometastases, the majority of patients with
positive sentinel nodes will not have pathologically
detected melanoma in the completion dissection speci-
men.
10 Furthermore, those patients who do have positive
nonsentinel nodes have a markedly higher risk of distant
metastases and may be beyond the reach of further pre-
ventative surgery.
11 Finally, the morbidity associated with
completion dissection is signiﬁcantly greater than that of
SLND for melanoma, so that the clinical cost of a negative
procedure is greater than with SLND alone. These factors
make completion of MSLT2, which randomizes patients
with positive sentinel nodes to completion lymph node
dissection or clinical observation with nodal ultrasound,
critical to rational management of regional lymph nodes in
melanoma.
Leiter and colleagues should be congratulated for their
analysis of SLND at Tuebingen. The close reproduction of
the MSLT1 results at this independent institution further
substantiates the ﬁndings of other retrospective series and
of the prospective trial. Observational studies such as theirs
add weight to the measured value of SLND and improve
the resolution of our picture of its survival impact.
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TABLE 1 Comparison of Leiter et al. and MSLT1 ﬁndings
Finding Leiter et al. MSLT 1
Multivariate OS hazard ratio (HR) of positive SLN 3.4 (1.8–6.4) p\0.001 2.48 (1.54–3.98) p\0.001
% Positive SLN versus control nodal recurrence 16.4% versus 16.4% 19.4% versus 18.5%
a
DFS beneﬁt in SLN groups 9.1% (76.9% versus 67.8%) 5.2% (78.3% versus 73.1%)
In-transit metastasis (SLN versus control) 9.2% versus 10.1% (p = 0.655) 7.7% versus 8.4% (p = 0.38)
HR for melanoma death: overall analysis 0.74 (0.52–1.05, p = 0.09) 0.92 (0.67–1.25, p = 0.58)
HR for melanoma death node ?: SLN versus Control 0.45 (0.25–0.71, p = 0.002)
b 0.62 (0.4–0.95, p = 0.02)
a Projected at 8 years
b Reported in the current article as the inverse: control versus SLN
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